DHL Supply Chain Acquires Healthcare Delivery Company SDS Rx

DHL Supply Chain, North America’s leading contract logistics provider, is strengthening its life sciences and healthcare capabilities by agreeing to acquire SDS Rx, a provider of final-mile delivery and specialized healthcare transportation for long-term care and specialty pharmacies, radiopharmacies and health system networks.

The strategic acquisition will further expand DHL’s healthcare logistics portfolio, enhancing the company’s ability to deliver integrated, time-critical solutions across every stage of the life sciences and healthcare supply chain.

Processing specialized healthcare deliveries from more than 200 locations across the U.S., SDS Rx will add final-mile logistics services to DHL’s healthcare transportation network. The acquisition will also expand DHL’s same-day and expedited delivery capabilities for life sciences and healthcare customers.

This will be the second healthcare acquisition for DHL Supply Chain in 2025, following its purchase of CryoPDP, a leading specialty courier focused on clinical trials, biopharmaceuticals as well as cell and gene therapies, earlier this year. Together, these acquisitions will mark a significant milestone for DHL Group and its strategic growth agenda under Strategy 2030, particularly in expanding its logistics offerings in the Life Sciences and Healthcare sector. They strengthen DHL’s capabilities across critical areas of the healthcare supply chain—from pharmaceuticals and consumer health to animal health and medical technology—while paving the way for further targeted growth. With enhanced expertise in cold chain management and specialty pharma logistics, DHL will be even better positioned to meet the complex needs of the healthcare industry and support further targeted growth.

DHL Supply Chain is committed to ensuring a seamless transition for customers and associates, with all employees becoming part of the DHL Supply Chain family. SDS Rx operations will be integrated into DHL Supply Chain North America’s Life Science & Healthcare business, and all teams will continue to operate under local leadership.

The closing of the acquisition is subject to regulatory approvals.

For more information, visit https://www.dhl.com.